Pacific Horizon Ventures

www.pacifichorizon.com

VCMatch tracks Pacific Horizon Ventures as an investor focused on Biotech, Pharma, and Medtech companies, Pre-Seed and Seed rounds, and United States and Seattle, Wa markets. Upload your deck to compare your startup against the full private matching profile.

Check Size

Not specified

Stages

Pre-Seed, Seed, Series A

Focus Areas

Biotech, Pharma, Medtech

Geography

United States and Seattle, WA

Investment Thesis

Pacific Horizon Ventures targets early-stage life sciences opportunities that can “change the societal healthcare equation” by addressing “significant healthcare problems in poorly served markets.” They prefer technologies that lead to product development (most often “based on biotechnology or pharmaceutical chemistry”) but remain receptive to medical devices, computational biology and genomics. PHV positions itself as an “active” investor that “take[s] a hands-on role in the general management of portfolio companies during the early stages of development,” leveraging principals who have “accumulated an in-depth knowledge of the life sciences” since the firm’s 1993 founding.

Is Pacific Horizon Ventures right for your startup?

Upload your pitch deck to compare your startup against VCMatch's private investor profile, including fit, timing, and next-step signals.

See If You're a Match View Sample Match

Investment Focus

Who should take a closer look

Pacific Horizon Ventures is most relevant for founders raising Pre-Seed, Seed, and Series A rounds in Biotech, Pharma, Medtech, and Digital Health, especially across United States and Seattle, WA.

Focus statement

PHV is "focused on the life sciences" and "invest[s] in early-stage in life science technologies that address significant healthcare problems in poorly served markets," with emphasis on biotech and pharmaceutical chemistry while being receptive to medical devices, computational biology and genomics.

Value Add

Hands-on, operational involvement: the firm says they "take a hands-on role in the general management of portfolio companies during the early stages of development."
Specialized, long-tenured team: "The four principals of Pacific Horizon Ventures have worked together for over a decade and have accumulated an in-depth knowledge of the life sciences."
Early-stage, high-impact mandate: they prioritize opportunities that can "change the societal healthcare equation" by targeting poorly served markets.
Broad modality acceptance within life sciences: while most often investing in biotech or pharmaceutical chemistry, they explicitly note receptivity to "medical devices, computational biology and genomics."
Proven track record and exits: portfolio history shows multiple acquisitions and partnerships (e.g., Illumigen acquired by Cubist, ViaCyte fundraising/partnership activity), demonstrating experience in developing and exiting early-stage life-science companies.